Related references
Note: Only part of the references are listed.Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E. Gerber et al.
LUNG CANCER (2020)
The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis
Wen-Ya Li et al.
BMC CANCER (2019)
Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines
Trista K. Hinz et al.
MOLECULAR PHARMACOLOGY (2019)
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target
Frank Aboubakar Nana et al.
CANCERS (2019)
Deletion of tetraspanin CD151 alters the Wnt oncogene-induced mammary tumorigenesis: A cell type-linked function and signaling
Hongxia Li et al.
NEOPLASIA (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
Matthew R. Janes et al.
CELL (2018)
Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
Emily K. Kleczko et al.
MOLECULAR CANCER (2018)
Differential Effector Engagement by Oncogenic KRAS
Tina L. Yuan et al.
CELL REPORTS (2018)
A systematic review of targeted agents for non-small cell lung cancer
Hannah H. Vestergaard et al.
ACTA ONCOLOGICA (2018)
Multiplatform-based molecular subtypes of non-small-cell lung cancer
F. Chen et al.
ONCOGENE (2017)
SIPA1 promotes invasion and migration in human oral squamous cell carcinoma by ITGB1 and MMP7
Toshikazu Takahara et al.
EXPERIMENTAL CELL RESEARCH (2017)
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation
Pingzhao Zhang et al.
NATURE MEDICINE (2017)
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer
Dennis O. Adeegbe et al.
CANCER DISCOVERY (2017)
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy
B. Xu et al.
ONCOGENESIS (2017)
Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas
Audrey Bouillez et al.
CANCER RESEARCH (2016)
New and emerging targeted treatments in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
LANCET (2016)
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Hong Jiang et al.
NATURE MEDICINE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
Suzanne F. Jones et al.
INVESTIGATIONAL NEW DRUGS (2015)
PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer
Duangmani Thanapprapasr et al.
MOLECULAR CANCER THERAPEUTICS (2015)
CD151-′3β1 integrin complexes are prognostic markers of glioblastoma and cooperate with EGFR to drive tumor cell motility and invasion
Pengcheng Zhou et al.
ONCOTARGET (2015)
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Ernest Nadal et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
Irina M. Shapiro et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier et al.
NATURE REVIEWS CANCER (2014)
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
Takeshi Shimamura et al.
CLINICAL CANCER RESEARCH (2013)
BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
Anna C. Belkina et al.
JOURNAL OF IMMUNOLOGY (2013)
RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas
Georgia Konstantinidou et al.
CANCER DISCOVERY (2013)
Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer
Noriaki Sunaga et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
Wolfram Brugger et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells
V. Morello et al.
ONCOGENE (2011)
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer
Hiu Wing Cheung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer
M. H. Lawson et al.
BRITISH JOURNAL OF CANCER (2010)
Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets
Christopher S. Stipp
EXPERT REVIEWS IN MOLECULAR MEDICINE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Integrin signaling and lung cancer
Francesca Caccavari et al.
CELL ADHESION & MIGRATION (2010)
Integrin signalling adaptors: not only figurants in the cancer story
Sara Cabodi et al.
NATURE REVIEWS CANCER (2010)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung
Ludmila Prudkin et al.
MODERN PATHOLOGY (2009)
CD151 accelerates breast cancer by regulating α6 integrin function, signaling, and molecular organization
Xiuwei H. Yang et al.
CANCER RESEARCH (2008)
MYC amplification in breast cancer: a chromogenic in situ hybridisation study
S. Maria Rodriguez-Pinilla et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Laminin 332 in squamous-cell carcinoma
M. Peter Marinkovich
NATURE REVIEWS CANCER (2007)
Epigenetic regulation of integrin-linked kinase expression depending on adhesion of gastric carcinoma cells
Yong-Bae Kim et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2007)
Multifaceted roles of Integrins in breast cancer metastasis
Donald E. White et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2007)
beta 1 integrin as a molecular therapeutic target
Nils Cordes et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2007)
Increased expression of integrin α3β1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line
T Yoshimasu et al.
CANCER SCIENCE (2004)
Share Paper
